TP53 and gastric cancer: Although the TCGA and ACRG classification systems provide a deeper understanding of tumor biology, robust evidence supporting their prognostic and therapeutic implications exists primarily for the MSS/TP53 [32], MSI [34], and EBV-positive [35] gastric cancer subtypes, based on biomarker analyses and clinical studies.